Our Portfolio

Human Immunology Biosciences (HI-Bio) is a US-based precision immunology company leveraging human genetics to deliver patient-targeted approaches to autoimmune disorders. HI-Bio is a new company that Monograph is co-incubating with Arch Venture Partners. Monograph co-led the Series A financing round in August 2021.

View site

AviadoBio is a UK-based gene therapy company with a program to treat an inherited form of frontotemporal dementia using pioneering novel routes of administration. Monograph co-led the Series A financing round with NEA in November 2021.

View site

Ascend is a specialist company innovating manufacturing processes to improve quality, potency, safety and cost enabling better reach for gene therapy technologies, initially focused on high-quality Adeno-associated virus (AAV) vectors. Ascend offers process development, clinical manufacturing, and analytical and regulatory support for biotech companies working in advanced modalities requiring flexible CMC services.

View site

Exited August 2022

Gilead Sciences to Acquire MiroBio for approx $405 million

MiroBio is a therapeutics company developing checkpoint agonist antibodies, a new class of therapies designed to restore immune balance and treat autoimmune disease. This work is based on 15 years of research from the University of Oxford. Monograph participated in the Series B financing round in June 2022.

View site

RegASK is a Singapore based global regulatory technology SaaS company enabling businesses in the biopharma, consumer health, medtech and food industries to leverage AI to strengthen and scale their regulatory and compliance capabilities. Monograph led the Series A financing in December 2022.

View Site

Maxion Therapeutics is a Cambridge, UK based company developing antibody drugs against ion channels and G-protein-coupled receptors (GPCRs) using proprietary KnotBody® platform to overcome challenges with this target class. Series A funding round was led by LifeArc Ventures, including Monograph Capital and BGF as equal participants.

View Site

ODAIA delivers a unique, AI-powered commercial insights platform that serves pharmaceutical companies. With its ability to provide near real-time and predictive perspective on the dynamic changes of the pharmaceutical marketplace, ODAIA’s proprietary platform MAPTUAL empowers leading life science brands to more efficiently get therapeutics, drugs and vaccines to the markets that need them with a modern, data-driven solution. Monograph co-led the Company’s Series B financing in April 2023.

View Site

UroGen Pharma is a US-headquartered biotech company developing and commercialising innovative solutions to treated urothelial and specialty cancers. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Monograph participated in a $120M private placement led by RA Capital and Great Point Partners which also included Acorn Bioventures and Horton Capital Partners.

View Site

Sudo is a US-based neuro-immunology company with R&D leadership based in the UK. The company is advancing a pipeline of TYK2 inhibitors for debilitating and highly prevalent diseases such as Multiple Sclerosis and Psoriasis. Monograph participated in the $147m Series B financing round in December 2023 co-led by Enavate Sciences and TPG Life Sciences Innovation, with participation from Frazier, Sanofi Ventures, Surveyor, and Eventide.

View Site

Nocion Therapeutics is a clinical-stage biopharmaceutical company developing an inhaled small molecule therapeutic, Taplucanium, with application in conditions such as cough, itch and pain. Monograph co-led the Series B financing with Arkin Bio Capital in February 2024, the proceeds of which are being used to run a phase IIb study in chronic cough.

View Site